
## Pouria Jandaghi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8070208/publications.pdf Version: 2024-02-01



Ροιιρίλ Ιλνολομι

#	Article	IF	CITATIONS
1	Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nature Communications, 2020, 11, 2416.	12.8	179
2	Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice. Gastroenterology, 2016, 151, 1218-1231.	1.3	100
3	A General Framework for Interrogation of mRNA Stability Programs Identifies RNA-Binding Proteins that Govern Cancer Transcriptomes. Cell Reports, 2018, 23, 1639-1650.	6.4	56
4	Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell carcinoma. Scientific Reports, 2017, 7, 44876.	3.3	42
5	Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer. Clinical Cancer Research, 2018, 24, 1987-2001.	7.0	37
6	<i>GHSR</i> DNA hypermethylation is a new epigenetic biomarker for gastric adenocarcinoma and beyond. Journal of Cellular Physiology, 2019, 234, 15320-15329.	4.1	15
7	The potential of dopamine receptor D2 (DRD2) as a therapeutic target for tackling pancreatic cancer. Expert Opinion on Therapeutic Targets, 2019, 23, 365-367.	3.4	12
8	<i>GHSR</i> hypermethylation: a promising pan-cancer marker. Cell Cycle, 2015, 14, 689-690.	2.6	10
9	Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma. Cancers, 2021, 13, 5825.	3.7	7
10	Aberration hubs in protein interaction networks highlight actionable targets in cancer. Oncotarget, 2018, 9, 25166-25180.	1.8	6